UNCY
Price:
$0.53
Market Cap:
$55.01M
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.[Read more]
Industry
Biotechnology
IPO Date
2021-07-12
Stock Exchange
NASDAQ
Ticker
UNCY
According to Unicycive Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 23.47M. This represents a change of 78.72% compared to the average of 13.13M of the last 4 quarters.
The mean historical Enterprise Value of Unicycive Therapeutics, Inc. over the last ten years is 32.82M. The current 23.47M Enterprise Value has changed 7.05% with respect to the historical average. Over the past ten years (40 quarters), UNCY's Enterprise Value was at its highest in in the December 2020 quarter at 75.00M. The Enterprise Value was at its lowest in in the June 2024 quarter at -20672001.52.
Average
32.82M
Median
27.68M
Minimum
7.83M
Maximum
78.75M
Discovering the peaks and valleys of Unicycive Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 84.99%
Maximum Annual Enterprise Value = 78.75M
Minimum Annual Increase = -81.43%
Minimum Annual Enterprise Value = 7.83M
Year | Enterprise Value | Change |
---|---|---|
2023 | 12.40M | 58.38% |
2022 | 7.83M | -46.44% |
2021 | 14.62M | -81.43% |
2020 | 78.75M | 84.99% |
2019 | 42.57M | 4.50% |
The current Enterprise Value of Unicycive Therapeutics, Inc. (UNCY) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
11.62M
5-year avg
31.23M
10-year avg
32.82M
Unicycive Therapeutics, Inc.’s Enterprise Value is greater than TransCode Therapeutics, Inc. (4.92M), less than Ambrx Biopharma Inc. (1.56B), greater than Cardio Diagnostics Holdings, Inc. (9.47M), greater than Hillstream BioPharma, Inc. (1.48M), less than SeqLL Inc. (81.77M),
Company | Enterprise Value | Market cap |
---|---|---|
4.92M | $6.64M | |
1.56B | $1.77B | |
9.47M | $10.73M | |
1.48M | $4.17M | |
81.77M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Unicycive Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Unicycive Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Unicycive Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Unicycive Therapeutics, Inc. (UNCY)?
What is the 3-year average Enterprise Value for Unicycive Therapeutics, Inc. (UNCY)?
What is the 5-year average Enterprise Value for Unicycive Therapeutics, Inc. (UNCY)?
How does the current Enterprise Value for Unicycive Therapeutics, Inc. (UNCY) compare to its historical average?